Valneva SE: 2025 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
Company: Valneva SE (VALN), a specialty vaccine company incorporated in France.
Reporting Period: Fiscal year ended December 31, 2025.
Core Business: Development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. Key commercial products include IXIARO (Japanese encephalitis), DUKORAL (cholera/ETEC), and IXCHIQ (chikungunya). The pipeline is anchored by VLA15 (Lyme disease, partnered with Pfizer) and S4V2 (Shigellosis, partnered with LimmaTech).
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (€ million) | 2024 (€ million) |
|---|---|---|
| Total Revenues | 174.7 | 169.6 |
| Product Sales | 157.9 | 163.3 |
| Operating Loss | (82.1) | 13.3 (Profit) |
| Net Loss | (115.2) | (12.2) |
| Adjusted EBITDA | (59.4) | 32.9 (Profit) |
| Cash and Cash Equivalents | 109.7 | 168.3 |
| Total Borrowings | 179.2 | 187.4 |
| Accumulated Net Loss | (679.1) | (563.9) |
Note: 2024 results included a one-time net gain of €90.8 million from the sale of a Priority Review Voucher (PRV).
Material Changes vs. Prior Period
- IXCHIQ Regulatory Actions: In August 2025, the FDA suspended the license for IXCHIQ due to serious adverse events (SAEs). In January 2026, Valneva voluntarily withdrew the U.S. Biologics License Application (BLA) and Investigational New Drug (IND) application. This led to €8.5 million in inventory write-offs and revaluation losses in 2025.
- Revenue Composition: Total revenue increased 3% to €174.7 million, driven by a €10.0 million revenue recognition from the Pfizer collaboration (Lyme disease) and growth in IXCHIQ sales (€8.4 million vs €3.7 million in 2024). This offset a 42% decline in third-party product sales due to terminated distribution agreements.
- Debt Refinancing: In October 2025, Valneva entered a new $500 million senior term loan facility with Pharmakon Advisors, replacing the previous Deerfield/OrbiMed facility. The initial $215 million tranche was drawn to repay prior debt. The new facility extends maturity to 2030 and carries a 9.00% fixed interest rate.
- Operational Restructuring: The company announced the closure of its Nantes, France site to consolidate operations in Lyon and Vienna, resulting in restructuring provisions.
Guidance, Outlook, and Risks
- Lyme Disease (VLA15): The pivotal Phase 3 VALOR trial data readout is expected in the first half of 2026. Success is critical for future milestone and royalty revenue. Failure to meet primary endpoints would trigger mandatory restructuring and cost-containment measures.
- IXCHIQ Outlook: The vaccine remains approved in the EU, Canada, UK, and Brazil, though with age restrictions in some jurisdictions. A pilot vaccination campaign is underway in Brazil. The U.S. market is currently closed.
- Liquidity: Management believes existing cash (€109.7 million) is sufficient to fund operations for at least 12 months following the report date.
- Internal Controls: The company identified a material weakness in internal controls over financial reporting related to complex, judgmental transactions (e.g., revenue recognition for the Pfizer agreement and inventory valuation). An adverse opinion was issued by auditors regarding internal controls.
- Manufacturing: An FDA inspection in February 2026 of the Livingston (Scotland) site resulted in a Form 483. The FDA denied approval for the new Almeida facility for U.S. distribution of IXIARO due to compliance issues, though the facility remains approved for EU/Canada. The Manson facility remains licensed for U.S. supply.
Key Facts for Investor Verification
- IXCHIQ Safety Data: Verify the status of ongoing regulatory reviews in the EU and other markets regarding SAEs in elderly populations and the impact on future sales volumes.
- VLA15 Phase 3 Timeline: Confirm the exact date of the VALOR trial data readout in H1 2026 and the specific criteria for success.
- Debt Covenants: Review the specific "going concern" and financial covenants in the new Pharmakon Loan Agreement and the conditions under which restructuring would be triggered if VLA15 data is negative.
- Remediation Plan: Assess the progress of the remediation plan for the material weakness in internal controls over financial reporting.
- Manufacturing Capacity: Monitor the resolution of FDA compliance issues at the Livingston site to ensure no long-term supply constraints for IXIARO in the U.S. market.